Cary Hyden is a partner and previously served as Chair of the Corporate Department in Orange County for almost 10 years. His practice focuses on mergers and acquisitions, capital markets, and general corporate and securities matters for companies, private equity sponsors and financial advisors. He has substantial experience representing companies in hostile takeover matters and in situations involving activist stockholders.
Mr. Hyden was named by Daily Journal to the list of "Top 100 Lawyers in California" in 2014 and 2015. He was also recognized by BTI Consulting Group, Inc. as an "All Star" for delivering superior client service based on interviews with general counsel and senior executive officers, and was one of only five lawyers in the nation to have received the "3 Year MVP" award.
Mr. Hyden has worked on more than 170 merger and acquisition transactions representing clients in a broad range of industry segments and has developed substantial experience representing:
- Pharmaceutical, biotech and healthcare companies such as Allergan, Avanir, Beckman Coulter, Edwards Lifesciences, Hospira, Proove Biosciences, Questcor and Trizetto
- Consumer, retail, apparel and action sports companies such as Volcom, Oakley, ASICS, Skullcandy, Tilly's, InterMix, Mossimo, Diesel S.p.A, Chrome Hearts, Fox Head, Rusty, St. John Knits, DC Shoes, Too Faced Cosmetics, prAna and Paul Frank
- Technology companies such as Broadcom, STEC, Quality Systems, OSI Systems, Kelley Blue Book, Mophie and Brand Affinity Technologies
- Real estate and mortgage banking companies such as William Lyon Homes, Quality Mortgage USA and Plaza Home Mortgage*
Recent mergers and acquisitions include:
- Allergan in connection with its US$72.8 billion sale to Actavis plc (recognized by The American Lawyer in its "Big Deal" section in January 2015 as the largest M&A transaction of 2014). Mr. Hyden was also recognized by The American Lawyer for his representation of Allergan on this transaction as a "Global M&A Deal of the Year: U.S.," in July 2015, “Dealmaker of the Year” in April 2015 and in the November 2014 “Dealmakers of the Week” section.
- Allergan in connection with the successful defense of US$54.6 billion unsolicited hostile takeover launched by Valeant along with activist hedge fund, Pershing Square Capital Management led by Bill Ackman (recognized by The American Lawyer in its “Big Deal” section in July 2014)
- Questcor Pharmaceuticals in its US$6.2 billion sale to Mallinckrodt PLC (recognized by The American Lawyer in its "Big Deal” section in May 2014)
- Beckman Coulter in connection with its US$6.8 billion sale to Danaher Corporation (recognized by The American Lawyer in its “Big Deal” section in 2011), its US$800 million "carve out" acquisition of the medical diagnostic business from a Japan-based manufacturer and its US$1.8 billion transaction with Biosite
- Volcom in its US$606 million sale to PPR S.A.
- DC Shoes in its US$150 million private company sale to Quiksilver
- Fox Head in its US$195 million sale to Altamont Capital Partners
- Oakley in its US$110 million acquisition of Eye Safety Systems, its acquisition of Optical Shop of Aspen and its acquisition of Oliver Peoples
Mr. Hyden also has worked on more than 75 capital markets transactions and he regularly handles public and private offerings of both equity and debt securities, representing both issuers and underwriters, including Goldman Sachs, Morgan Stanley, Credit Suisse, Deutsche Bank and Bank of America Merrill Lynch.
Mr. Hyden has led recent IPOs for Volcom, Tilly's, William Lyon Homes and Skullcandy and has led debt or convertible offerings for Allergan, William Lyon Homes and Beckman Coulter.
*Represents experience from a previous law firm.